EcoDrugPlus

Serpin Peptidase Inhibitor, Clade C (Antithrombin), Member 1

Ensembl ID : ENSXETG00000020033
Gene Symbol: SERPINC1
5 View Cross-references
201 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sigma Non-Opioid Intracellular Receptor 1

Ensembl ID : ENSXETG00000047722
Gene Symbol: SIGMAR1
5 View Cross-references
205 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sirtuin 1

Ensembl ID : ENSXETG00000023588
Gene Symbol: SIRT1
8 Enzyme and pathways 5 View Cross-references
157 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSXETG00000014939
Gene Symbol: SMO
9 Enzyme and pathways 5 View Cross-references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Channel, Non Voltage Gated 1 Alpha Subunit

Ensembl ID : ENSXETG00000018954
Gene Symbol: SCNN1A
6 Enzyme and pathways 5 View Cross-references
153 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Channel, Non Voltage Gated 1 Beta Subunit

Ensembl ID : ENSXETG00000027567
Gene Symbol: SCNN1B
5 View Cross-references
151 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Channel, Non Voltage Gated 1 Gamma Subunit

Ensembl ID : ENSXETG00000012423
Gene Symbol: SCNN1G
6 Enzyme and pathways 5 View Cross-references
155 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Channel, Voltage Gated, Type Iv Alpha Subunit

Ensembl ID : ENSXETG00000014235
Gene Symbol: SCN4A
5 View Cross-references
190 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium Channel, Voltage Gated, Type Viii Alpha Subunit

Ensembl ID : ENSXETG00000008958
Gene Symbol: SCN8A
3 Enzyme and pathways 5 View Cross-references
274 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sodium/glucose Cotransporter 1-Like

Ensembl ID : ENSXETG00000040151
Gene Symbol: LOC116406445
6 Enzyme and pathways 5 View Cross-references
250 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Solute Carrier Family 18 Member A2

Ensembl ID : ENSXETG00000046436
Gene Symbol: SLC18A2
10 Enzyme and pathways 5 View Cross-references
223 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Solute Carrier Family 22 Member 6-A

Ensembl ID : ENSXETG00000035704
Gene Symbol: LOC100490946
5 Enzyme and pathways 4 View Cross-references
277 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).